Pharma BD Deal Intelligence
Cabaletta Bio, Inc. / IASO Biotherapeutics
2022 · Licensing/Option · $162M · Pending
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2027 at the earliest for this deal, once/if it closes.
Key facts
- Announced Oct 11, 2022
- Deal value $162M
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2022 deals